title: Impact of thromboprophylaxis across the US acute care setting.
abstract: BACKGROUND
  The risk of venous thromboembolism (VTE) can be reduced by appropriate use of anticoagulant prophylaxis. VTE prophylaxis does, however, remain substantially underused, particularly among acutely ill medical inpatients. We sought to evaluate the clinical and economic impact of increasing use of American College of Chest Physicians (ACCP)-recommended VTE prophylaxis among medical inpatients from a US healthcare system perspective.
  
  
  RESULTS
  In this retrospective database cost-effectiveness evaluation, a decision-tree model was developed to estimate deaths within 30 days of admission and outcomes attributable to VTE that might have been averted by use of low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH). Incremental cost-effectiveness ratio was calculated using "no prophylaxis" as the comparator. Data from the ENDORSE US medical inpatients and the US nationwide Inpatient Sample (NIS) were used to estimate the annual number of eligible inpatients who failed to receive ACCP-recommended VTE prophylaxis. The cost-effectiveness analysis indicated that VTE-prevention strategies would reduce deaths by 0.5% and 0.3%, comparing LMWH and UFH strategies with no prophylaxis, translating into savings of $50,637 and $25,714, respectively, per death averted. The ENDORSE findings indicated that 51.1% of US medical inpatients were at ACCP-defined VTE risk, 47.5% of whom received ACCP-recommended prophylaxis. By extrapolating these findings to the NIS and applying cost-effectives analysis results, the full implementation of ACCP guidelines would reduce number of deaths (by 15,875 if using LMWH or 10,201 if using UFH), and was extrapolated to calculate the cost reduction of $803M for LMWH and $262M for UFH.
  
  
  CONCLUSIONS
  Efforts to improve VTE prophylaxis use in acutely ill inpatients are warranted due to the potential for reducing VTE-attributable deaths, with net cost savings to healthcare systems.
authors: Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
authors: Wei
authors: W
authors: Huang
authors: Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
authors: Frederick A
authors: FA
authors: Anderson
authors: Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America.
authors: Sophie K
authors: SK
authors: Rushton-Smith
authors: Department of Haematological Medicine, Guys and St Thomas' NHS Foundation Trust, King's College, London, United Kingdom.
authors: Alexander T
authors: AT
authors: Cohen
mesh_terms: D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000191:economics; D003430:Cross-Sectional Studies; D006493:Heparin / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D065129:Pre-Exposure Prophylaxis / Q000191:economics* / Q000379:methods; D011446:Prospective Studies; D014481:United States; D054556:Venous Thromboembolism / Q000191:economics / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin